LeadMed

About LeadMed

LeadMed, commercially known as GenomiCare Biotechnology (领星生物), is a biotechnology company focused on providing real-world data solutions for the oncology sector. Founded in 2015 by Dr. Xu Qiang, the company is headquartered in Shanghai, China, with a branch in the United States. Dr. Xu, who serves as president and CEO, co-founded the company with Carebridge Holdings to offer comprehensive precision medicine services for cancer patients in China.

The company operates in the precision medicine and real-world data market, serving global pharmaceutical and biotechnology companies. Its business model revolves around leveraging its extensive database of clinical and genomic data to accelerate oncology drug research, development, and commercialization. By integrating deep molecular and clinical data with artificial intelligence and proprietary analytics, LeadMed provides data-driven solutions that help in forming, optimizing, and validating clinical hypotheses for cancer therapeutics.

LeadMed's core service is its clinical intelligent analysis platform, built upon a comprehensive clinical-molecular knowledge base. The company gathers real-world data, including genomic information, in-depth clinical data, and long-term follow-up data from Chinese cancer patients through direct consent. This platform enables it to offer services such as biomarker discovery, target identification and validation, and evaluation of post-market drug safety and efficacy. The company initially focused on providing individualized diagnosis and treatment services to Chinese cancer patients and doctors, helping them find the most suitable clinical treatment options. As of June 2019, its platform had served over ten thousand clients, creating China's largest clinical exome oncology database.

The firm has established laboratories and medical testing facilities and collaborates with institutions like the Peking University School of Life Sciences. LeadMed has secured significant funding to support its growth, including a Series A round in November 2017 involving Morningside Venture Capital, Apricot Capital, and Carebridge Holdings, bringing its total capital raised to $25 million since its inception.